Basit öğe kaydını göster

dc.contributor.authorErtenli, I
dc.contributor.authorKiraz, S
dc.contributor.authorCelik, I
dc.contributor.authorHaznedaroglu, IC
dc.contributor.authorErman, M
dc.contributor.authorCalguneri, M
dc.contributor.authorKirazli, S
dc.date.accessioned2019-12-10T11:10:45Z
dc.date.available2019-12-10T11:10:45Z
dc.date.issued2001
dc.identifier.issn0003-4967
dc.identifier.urihttps://doi.org/10.1136/ard.60.12.1149
dc.identifier.urihttp://hdl.handle.net/11655/14905
dc.description.abstractBackground-Tissue factor pathway inhibitor (TFPI) is an anticoagulant which modulates the tissue factor (TF) dependent pathway, acting on the factor VIIa/TF complex, factor Xa, and thrombin. Although most TFPI is found in association with plasma lipoproteins and platelets, the functional pool is bound to vascular endothelium and is released into the circulation on stimulation with heparin or low molecular weight heparin (LMWH). Objective-To assess the vascular endothelial TFPI pool in patients with Behcet's disease (BD) or systemic lupus erythernatosus (SLE). Methods-Plasma TFP1 concentrations were determined before, and 20 and 60 minutes after subcutaneous LMWH injection in 15 newly diagnosed patients with BD and 12 with SLE, and in 12 healthy controls. Results-Baseline median TFPI was 149.5 ng/ml in healthy subjects, and the percentage change in TFPI at 20 minutes (((value at 20th min - baseline value)/baseline value) x 100) was 575.2. TFP1 concentrations in patients with BD were initially normal at baseline (136.0 ng/ml), but the percentage change (44.7) was significantly lower than in the patients with SLE and the controls. Baseline TFPI concentrations in patients with SLE (83.0 ng/ml) were lower than in the control group, but the TFPI response to stimulation with LMWH reached a level (626.4%) comparable to that of the controls. Conclusion-Depletion of the functional endothelial pool in BD and low circulating concentrations of TFPI despite an intact pool in SLE may be important in the pathogenesis of thrombosis in these vasculitic syndromes.
dc.language.isoen
dc.publisherBritish Med Journal Publ Group
dc.relation.isversionof10.1136/ard.60.12.1149
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectRheumatology
dc.titleChanges In The Concentration And Distribution Of Tissue Factor Pathway Inhibitor In Behcet'S Disease And Systemic Lupus Erythematosus: Effect On The Prethrombotic State
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalAnnals Of The Rheumatic Diseases
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume60
dc.identifier.issue12
dc.identifier.startpage1149
dc.identifier.endpage1151
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster